Search
for
Sort by
Research 361–390 of 1000+
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- Emerging drugs for alopecia areata: JAK inhibitors
- Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
- Mesenchymal Stem Cells Antagonize IFN-Induced Proinflammatory Changes and Growth Inhibition Effects via Wnt/β-Catenin and JAK/STAT Pathway in Human Outer Root Sheath Cells and Hair Follicles
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
- Response of alopecia areata of the beard to oral tofacitinib
- Interleukin 6 and STAT3 regulate p63 isoform expression in keratinocytes during regeneration
- Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
- Janus kinase inhibitors for alopecia areata
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Topical tofacitinib for the treatment of alopecia areata affecting facial hair
- Alopecia areata flare patterns in children and young adults while on systemic tofacitinib
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
- Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
- Acne exacerbation after tofacitinib treatment for alopecia areata
- A review of Janus kinase inhibitor use in scarring alopecia
- Biologics in the management of childhood atopic dermatitis
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- Real-world experience quantifying access to JAK inhibitor care for alopecia areata patients: a patient-centered survey study
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Alopecia – New building blocks
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- Alopecia universalis successfully treated with tofacitinib
- Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion